Market
How many patients will receive 'King Kong' weight-loss drug in England by end of 2025?
2
Resolution / Starting Odds
Less than 100,000 • 25%
100,000 to 150,000 • 25%
150,001 to 220,000 • 25%
More than 220,000 • 25%
NHS official reports and announcements
Story
NHS Plans 12-Year Rollout for 'King Kong' Weight-Loss Drug, Limited to 220,000 Patients
Dec 5, 2024, 01:11 AM
The National Health Service (NHS) in England has announced a 12-year rollout plan for a new weight-loss drug, which has been described as the 'King Kong' of weight-loss treatments. This drug, anticipated to be a significant player in the Chinese market worth over $11 billion annually by 2033 according to Nomura, will initially be limited to just 220,000 patients, fewer than one in ten who meet the eligibility criteria. The slow rollout is due to concerns that the demand for the drug could overwhelm the health service, leading to a long wait for millions of severely obese patients.
View original story
Similar markets
200 to 400 • 25%
Less than 200 • 25%
400 to 600 • 25%
More than 600 • 25%
Availability/shortages • 25%
Financial cost • 25%
Drug efficacy • 25%
Off-label use • 25%
40 to 60 • 25%
More than 60 • 25%
Less than 20 • 25%
20 to 40 • 25%
Eli Lilly's Zepbound • 25%
Novo Nordisk's semaglutide 7.2 mg • 25%
No new major approvals • 25%
A new drug from another company • 25%
Other • 25%
Saxenda • 25%
Wegovy • 25%
Zepbound • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Pfizer • 25%
Novo Nordisk • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Other • 25%
Novo Nordisk • 25%
Other • 25%
Viking Therapeutics • 25%
Eli Lilly • 25%
Equal market share • 25%
Orforglipron leads • 25%
Injectables lead • 25%
Other drugs lead • 25%
10% to 20% • 25%
More than 30% • 25%
Less than 10% • 25%
20% to 30% • 25%
Eli Lilly • 33%
Novo Nordisk • 33%
Another competitor • 34%